US pharmaceutical company AstraZeneca Plc (LON: AZN) (STO: AZN) announced on 23 November 2020 that its experimental COVID-19 vaccine has shown an average efficacy of 70% in its large scale trials, CNN reported on Monday.
This vaccine, developed with the University of Oxford, showed 90% efficacy in one dosing regimen and 62% efficacy in a second regimen, which averages to a 70% efficacy, AstraZeneca said.
In a news release, AstraZeneca said that its vaccine was "highly effective in preventing COVID-19, the primary endpoint, and no hospitalisations or severe cases of the disease were reported in participants receiving the vaccine."
According to the company, the interim analysis included a total of 131 COVID-19 cases.
This comes after Moderna announced earlier this month that its vaccine was 94.5% effective against COVID-19 and Pfizer announced its vaccine was 95% effective, CNN added.
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses